Safety and efficacy of 177Lu-PSMA-I&T Radioligand Therapy in Octogenarians with metastatic castration-resistant prostate cancer: Report on eighty patients over age eighty

S. Grigorascu,Robert Tauber,Karina Knorr,Margitta Retz,Isabel Rauscher, K. Hansen, Calogero D’Alessandria,Hans Wester, J. Gschwend,Wolfgang Weber, M. Eiber,Thomas Langbein

Nuklearmedizin-nuclear Medicine（2023）

引用 0|浏览7

暂无评分

摘要

Ziel/Aim 177Lu-PSMA radioligand (RLT) therapy is a new treatment option for metastatic castration-resistant prostate cancer (mCRPC). Its low toxicity profile favors the use in elderly patients. Purpose of this study was to evaluate the safety and efficacy of 177Lu-PSMA-RLT in mCRPC patients≥80 years of age.

查看译文

关键词

prostate cancer,lu-psma-i,castration-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要